Pyxis Oncology (NASDAQ:PYXS) Stock Rating Raised to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Pyxis Oncology (NASDAQ:PYXS) from a sell rating to a hold rating in a research note published on Saturday morning,Wall Street Zen reports.

Several other brokerages have also recently issued reports on PYXS. Wells Fargo & Company boosted their price objective on shares of Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pyxis Oncology in a research report on Friday, September 25th. Stifel Nicolaus set a $5.00 target price on Pyxis Oncology in a research report on Thursday. Royal Bank Of Canada boosted their price target on Pyxis Oncology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday. Finally, Wedbush dropped their price target on Pyxis Oncology from $8.00 to $7.00 and set an “outperform” rating for the company in a research note on Friday. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.71.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $1.66 on Friday. Pyxis Oncology has a 1 year low of $1.03 and a 1 year high of $5.55. The firm has a 50 day moving average price of $2.51 and a 200 day moving average price of $2.16. The company has a market cap of $138.46 million, a price-to-earnings ratio of -1.28 and a beta of 1.41.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. Sell-side analysts predict that Pyxis Oncology will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Several institutional investors and hedge funds have recently bought and sold shares of PYXS. Commonwealth Equity Services LLC grew its stake in shares of Pyxis Oncology by 14.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company’s stock worth $114,000 after purchasing an additional 6,295 shares during the last quarter. T3 Companies LLC acquired a new stake in Pyxis Oncology during the third quarter valued at approximately $61,000. Finally, Renaissance Technologies LLC lifted its stake in Pyxis Oncology by 22.0% during the first quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after purchasing an additional 160,300 shares during the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.